The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 17, 2020

Filed:

Apr. 28, 2017
Applicant:

Tamir Biotechnology, Inc., Short Hills, NJ (US);

Inventors:

Jamie Sulley, La Jolla, CA (US);

Luis Squiquera, Buenos Aires, AR;

David Sidransky, Pikesville, MD (US);

Tom Hodge, Athens, GA (US);

Assignee:

ORGENESIS INC., Germantown, MD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/54 (2006.01); A61K 39/21 (2006.01); C07K 14/16 (2006.01); C07K 7/08 (2006.01); C12N 15/86 (2006.01); A61K 38/46 (2006.01); A61K 9/00 (2006.01); A61K 35/744 (2015.01); A61K 35/747 (2015.01); C12N 9/22 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 9/0014 (2013.01); A61K 9/0034 (2013.01); A61K 35/744 (2013.01); A61K 35/747 (2013.01); A61K 38/465 (2013.01); C07K 7/08 (2013.01); C07K 14/16 (2013.01); C12N 9/22 (2013.01); C12N 15/86 (2013.01); C12Y 301/27005 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); A61K 48/00 (2013.01); A61K 2039/525 (2013.01); A61K 2039/53 (2013.01); C12N 2740/16043 (2013.01); C12N 2740/16334 (2013.01); C12Y 301/27 (2013.01);
Abstract

An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.


Find Patent Forward Citations

Loading…